9 results about "Lymphangiogenesis" patented technology

The present disclosure relates to systems, devices, and methods for subcutaneously cutting and treating tissue and cellulite with non-invasive acoustic waves. Embodiments of the present disclosure refer to systems, devices, and methods that use unfocused or planar, non-cavitating acoustic waves to induce physical effects in tissue such as dermis, fat, muscle, bone, blood vessels, liver tissue, etc. The physical effects include disruption of the fibrous extracellular matrix of the target tissue. Embodiments of the present disclosure include the application of multiple rapid acoustic pulses (e.g., shockwaves) to cause the breakdown of the fibrous extracellular matrix to reduce the appearance of cellulite or scarring in the treated area. Such unfocused or planar, non-cavitating acoustic waves can induce tissue responses such as reduced fibrosis, induction of angiogenesis or lymphangiogenesis, etc.

The present disclosure relates generally to the treatment of glaucoma and / or the reduction of elevated intraocular pressure (IOP). In particular, the present disclosure relates to compositions and methods for preventing or treating glaucoma, including primary glaucoma, by inhibiting factors associated with ocular lymphangiogenesis.

A method of inducing lymphangiogenesis in the brain or central nervous system of a subject is provided in which an effective amount of a lymphangiogenesis inducer is administered. A method of inducing lymphangiogenesis in a tumor in the brain or central nervous system of a subject is provided in which an effective amount of a lymphangiogenesis inducer is administered. A method of treating a cancer of the brain or central nervous system is also provided in which an effective amount of a lymphangiogenesis inducer is administered. An example of a lymphangiogenesis inducer is VEGFC. The lymphangiogenesis inducer can be in the form of a protein or a polynucleotide encoding the protein, such as an mRNA or AAV. The lymphangiogenesis inducer can be administered to the cistema magna or directly into the lymphatic system. An immunotherapeutic agent, such as a checkpoint inhibitor, may also be administered.

The present disclosure relates to compounds that modulate the activity of transcription factor SOX18. More particularly, due to the modulation of transcription factor SOX18, the compounds present as useful therapies in the treatment of angiogenesis- and lymphangiogenesis- related diseases, disorders, or conditions.

A lymphangiogenesis inducing device includes: a rod configured to be inserted into a living tissue; and a wound application unit that is provided on the rod and configured to provide a fine wound to a target site of the living tissue. The wound application unit includes an edge formed on an outer periphery of the rod, and is configured to apply the wound to the target site upon rotation of the rod around a central axis.

This invention discloses the application of lncRNA MAGE-A10-encoded short peptide in regulating lymph node metastasis and targeted therapy in bladder cancer, belonging to the field of biomedical technology. This invention focuses on the coding ability of long non-coding RNAs, using high-throughput sequencing and bioinformatics algorithms to screen for lncRNA MAGE-A10, which is highly expressed in lymph node metastasis-positive bladder cancer tissues. The coding ability was verified by predicting open reading frames, constructing expression vectors, and synthesizing specific antibodies. The encoded short peptide MAGE-A10-44aa was positively correlated with lymph node metastasis in bladder cancer and poor patient prognosis, and also promoted lymphangiogenesis and lymph node metastasis in bladder cancer. This confirms the biological role of the MAGE-A10-44aa short peptide in bladder cancer lymph node metastasis, providing a potential target for bladder cancer treatment.

The present invention relates to a method for reducing blood pressure by stimulating lymphatic vessel growth and / or lymphangiogenesis in the kidneys.

Lymphedema is a chronic condition causes by a lymphatic dysfunction that leads to the accumulation of fluid and fat in the limb. Here, the inventors identified the bioactive peptide apelin as good candidate to restore the lymphatic flow in lymphedema. They found a significant decrease in apelin expression in women lymphedematous arm compared to their normal arm. Using an apelin-knockout mouse model, they confirmed the crucial role of apelin as lymphedema was maintained more than 4 weeks after surgery and was associated with a lack of dermis lymphangiogenesis and increased dermal backflow. The inventors show that intradermal injection of apelin-lentivector significantly reduced limb swelling. This was associated with a reduction of dermis fibrosis and increase in lymphatic density. Importantly, apelin stimulates eNOS-mediated lymphatic pumping via Akt and eNOS phosphorylation in lymphatic endothelial cells (LEC). This was associated with significant increase in E2F8-targeted gene expression through the direct binding of E2F8 on CCBE1 promoter in LEC. Taken together, the results show that apelin plays a key role in lymphedema and thus represents a novel partner for VEGF-C to prevent limb swelling and tissue fibrosis in lymphedema.